Safety of MP470 in Combination With Standard-of-Care Chemotherapy Regimens to Treat Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
Malignant Disease
Interventions
DRUG

MP-470 + topotecan

Topotecan 1.5 mg/m2 IV infusion over 30 minutes on Days 1-5

DRUG

MP-470 + docetaxel

Docetaxel 75 mg/m2 IV infusion over 1 hour on Day 1

DRUG

MP-470 + erlotinib

150 mg PO once daily at least 1 hour before or 2 hours after eating

DRUG

MP-470 + paclitaxel/carboplatin

Paclitaxel 200 mg/m2 IV infusion over 3 hours followed by carboplatin IV infusion over 1 hour to a target AUC of 6 mg∙min/mL on Day 1

DRUG

MP-470 + carboplatin/etoposide

Carboplatin IV infusion over 1 hour to target AUC of 5 mg min/mL on Day 1 followed by etoposide 100 mg/m2 IV infusion over 2 hours on Days 1-3

Trial Locations (5)

78229

Audie Murphy Veterans Memorial Hospital (VA), San Antonio

CTRC at the UT Health Science Center at San Antonio, San Antonio

South Texas Accelerated Research Therapy (START), San Antonio

85258

Premiere Oncology, Scottsdale

90404

Premiere Oncology, Santa Monica

Sponsors
All Listed Sponsors
lead

Astex Pharmaceuticals, Inc.

INDUSTRY